[어바웃 C] 팜젠사이언스, R&D 핵심축 이탈…박희덕 단독대표 이중고

PharmGen Science's transition from co-CEOs to a sole CEO raises concerns about R&D continuity as the retiring co-CEO had overseen drug development. The CEO now faces dual pressures: advancing clinical trials for next-generation drugs (RD1301, RD1305) while managing declining profitability, with R&D and marketing costs expected to surge. The company's ability to balance innovation investment with financial health will be critical to stakeholder confidence.